This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

This study has been completed.
Information provided by:
DexCom, Inc. Identifier:
First received: April 13, 2010
Last updated: April 14, 2010
Last verified: April 2010

The purpose of this study is to evaluate the effectiveness of the Continuous Glucose Monitoring System (DexCom™ SEVEN PLUS®) and to evaluate the impact of CGM on glycemic control when worn for up to 6-months by subjects 18 to 70 years-old with Type 1 diabetes mellitus on MDI or CSII therapy.

The primary objective of this study is to demonstrate no statistically significant differences between MDI and CSII subjects in terms of A1C change at 6 months as compared to baseline. A secondary objective is to evaluate time spent outside of the euglycemic region (70 to 180 mg/dL) from the baseline (blinded month) to the conclusion of 6 month follow-up.

Safety data of the SEVEN PLUS System will also be collected and safety will be characterized by the incidence of Adverse Device Effects, Serious Adverse Device Events, and Unanticipated Adverse Device Effects experienced by study participants.

Condition Intervention
Type 1 Diabetes Mellitus Device: CGM

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

Resource links provided by NLM:

Further study details as provided by DexCom, Inc.:

Estimated Enrollment: 120
Study Start Date: April 2009
Groups/Cohorts Assigned Interventions
Subject on multiple Daily Injections
Device: CGM
Continuous Glucose Monitoring System
Subjects on Continuous Subcutaneous Insulin Infusion
Device: CGM
Continuous Glucose Monitoring System


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This clinical study population will consist of a minimum of 100, and up to 120 subjects with insulin-requiring diabetes mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) therapy; equal number of subjects will be enrolled among each therapy group. It is desirable to have a similar distribution of baseline A1C in each study group.

Inclusion Criteria:

  1. Age 18 to 70 years;
  2. Have been diagnosed with Type 1 diabetes at least 3 years;
  3. Have been treated on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy for at last 6 months;
  4. Willing not to switch method of insulin delivery (i.e., MDI to CSII, or CSII to MDI) while enrolled in this study;
  5. Baseline A1C within 6.5% to 10.0% (may be determined by POC measurement, e.g., DCA 2000 to assess this inclusion criterion);
  6. Patients on MDI should be on a stable dose of peak-less insulin (e.g., Lantus) once or twice a day along with any rapid acting prandial insulin analog (e.g., Humalog, Novolog, or Apidra);
  7. Willing not to inject insulin or wear an insulin pump insertion set within 3 inches from the Sensor site during Sensor wear;
  8. Willing to use only the blood glucose meter(s) provided to them for self-monitoring of blood glucose (SMBG) during Sensor wear;
  9. Willing to take a minimum of 4 fingersticks per day during home use (2 for calibration purposes, 2 for comparative purposes);
  10. Willing to refrain from the use of acetaminophen during the Sensor insertion period and for at least 24-hours prior to Sensor insertion;
  11. Willing not to schedule a magnetic resonance (MRI) scan, computed tomography (CT) scan, or x-ray, for the duration of the study;
  12. Able to speak, read, and write English.

Exclusion Criteria:

  • 1. Have extensive skin changes/diseases that preclude wearing the Sensor on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites; 2. Subjects who have a known allergy to medical-grade adhesives; 3. Are pregnant as demonstrated by a positive pregnancy test within 72 hours of insertion or are planning to become pregnant during the course of study; 4. Have a hematocrit that is less than 30%, or greater than 55%; 5. Current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study); 6. Have used CGM for 6 or more weeks (combined) during the 3 months prior to enrollment; 7. Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis B or C).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01104142

United States, Colorado
Barbara Davis Center for Childhood Diabetes
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
DexCom, Inc.
Study Chair: Andrew K Balo DexCom, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Andrew K. Balo/SVP, Clinical and Regulatory Affairs, and Quality Assurance, DexCom, Inc Identifier: NCT01104142     History of Changes
Other Study ID Numbers: PTL-900222
Study First Received: April 13, 2010
Last Updated: April 14, 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 22, 2017